Erik Hugger J.
- Country
- Denmark
- Department
- Oncology
Research Overview
- Phase 3 Randomized Study of Sacituzumab Tirumotecan and Pembrolizumab Versus Physician's Choice in Triple-Negative Breast Cancer Post-Neoadjuvant Therapy
- A translational RANDOMIZED phase III study exploring the effect of the addition of capecitabine to Carboplatinum based chemotherapy in early “triple negative” breast cancer
- Comparison of FDG-PET/CT and Conventional CT for Response Monitoring in Metastatic Breast Cancer: A Multicenter Randomized Clinical Trial
Data & Insights
Has run more than one trial at 182 of 448 partner sites.
Specializations
Advanced Breast Cancer Management
The investigator specializes in treating hormone receptor-positive (HR+) and HER2-negative advanced breast cancer, exploring innovative therapeutic approaches through combination treatments and targeted therapies.
- Metastatic Disease Management
- Endocrine Therapy Optimization
- Treatment Response Monitoring
Their research encompasses novel imaging techniques including FDG-PET/CT for response monitoring in metastatic cases.
Early-Stage Breast Cancer
Focuses on developing treatment strategies for early triple-negative breast cancer and high-risk HER2-positive breast cancer with particular attention to neoadjuvant therapy approaches.
- Preoperative Chemotherapy Protocols
- Pathologic Response Assessment
- Post-Neoadjuvant Treatment
Investigates combination therapies including carboplatin-based chemotherapy regimens for optimal outcomes.
Supportive Care in Cancer
Addresses quality of life concerns in breast cancer patients, particularly focusing on managing treatment-related vasomotor symptoms in women undergoing hormone therapy.
- Symptom Management
- Treatment Side Effects
- Patient Quality of Life
Evaluates novel therapeutic approaches for managing moderate to severe hot flashes in cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.